United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Cuts Stock Position in Zoetis Inc. $ZTS

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.4% in the third quarter, HoldingsChannel.com reports. The fund owned 221,041 shares of the company’s stock after selling 5,400 shares during the period. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Zoetis were worth $32,343,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. CIBC Asset Management Inc increased its stake in Zoetis by 4.3% during the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock worth $36,745,000 after buying an additional 10,434 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp lifted its position in shares of Zoetis by 6.5% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after acquiring an additional 18,040 shares in the last quarter. Ninety One UK Ltd boosted its stake in shares of Zoetis by 19.6% in the third quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock worth $163,751,000 after acquiring an additional 183,686 shares during the last quarter. Quilter Plc boosted its stake in shares of Zoetis by 10.2% in the third quarter. Quilter Plc now owns 438,959 shares of the company’s stock worth $64,228,000 after acquiring an additional 40,615 shares during the last quarter. Finally, Swedbank AB increased its position in shares of Zoetis by 60.4% during the third quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock worth $356,565,000 after purchasing an additional 917,598 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

NYSE ZTS opened at $121.54 on Friday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The stock’s fifty day moving average is $126.06 and its two-hundred day moving average is $133.05. The firm has a market capitalization of $51.31 billion, a P/E ratio of 20.19, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.00.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same period last year, the company earned $1.40 EPS. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Morgan Stanley set a $160.00 price objective on Zoetis in a report on Thursday, December 18th. Barclays initiated coverage on shares of Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price for the company. KeyCorp assumed coverage on shares of Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating on the stock. Stifel Nicolaus lowered their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday, November 18th. Finally, BTIG Research reaffirmed a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research note on Thursday, February 26th. Six research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.